Advances in CAR-T therapy for central nervous system tumors
Abstract The application of chimeric antigen receptor T-cell therapy in central nervous system tumors has significantly advanced; however, challenges pertaining to the blood-brain barrier, immunosuppressive microenvironment, and antigenic heterogeneity continue to be encountered, unlike its success...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Book |
| Published: |
BMC,
2024-11-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_60954a8e09d34cf2a8244022f988b5b1 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Delian Zhou |e author |
| 700 | 1 | 0 | |a Xiaojian Zhu |e author |
| 700 | 1 | 0 | |a Yi Xiao |e author |
| 245 | 0 | 0 | |a Advances in CAR-T therapy for central nervous system tumors |
| 260 | |b BMC, |c 2024-11-01T00:00:00Z. | ||
| 500 | |a 10.1186/s40364-024-00679-6 | ||
| 500 | |a 2050-7771 | ||
| 520 | |a Abstract The application of chimeric antigen receptor T-cell therapy in central nervous system tumors has significantly advanced; however, challenges pertaining to the blood-brain barrier, immunosuppressive microenvironment, and antigenic heterogeneity continue to be encountered, unlike its success in hematological malignancies such as acute lymphoblastic leukemia and diffuse large B-cell lymphomas. This review examined the research progress of chimeric antigen receptor T-cell therapy in gliomas, medulloblastomas, and lymphohematopoietic tumors of the central nervous system, focusing on chimeric antigen receptor T-cells targeting antigens such as EGFRvIII, HER2, B7H3, GD2, and CD19 in preclinical and clinical studies. It synthesized current research findings to offer valuable insights for future chimeric antigen receptor T-cell therapeutic strategies for central nervous system tumors and advance the development and application of this therapeutic modality in this domain. | ||
| 546 | |a EN | ||
| 690 | |a Central nervous system tumors | ||
| 690 | |a Chimeric antigen receptor T-cell therapy | ||
| 690 | |a Glioblastoma | ||
| 690 | |a Medulloblastoma | ||
| 690 | |a Central nervous system lymphoma | ||
| 690 | |a Central nervous system acute lymphoblastic leukemia | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Biomarker Research, Vol 12, Iss 1, Pp 1-36 (2024) | |
| 787 | 0 | |n https://doi.org/10.1186/s40364-024-00679-6 | |
| 787 | 0 | |n https://doaj.org/toc/2050-7771 | |
| 856 | 4 | 1 | |u https://doaj.org/article/60954a8e09d34cf2a8244022f988b5b1 |z Connect to this object online. |